Skip to main content
Premium Trial:

Request an Annual Quote

UK Hospital Using Biomerieux Nucleic Acid-Extraction System


Biomérieux said this week that the virology laboratory at Aberdeen Royal Infirmary in the UK is using Biomérieux's NucliSENS easyMAG automated nucleic acid-extraction system for quantitative PCR-based virus screening.

According to Biomérieux, easyMAG is an IVD-labeled automated system for extracting total nucleic acids from a variety of sample types and volumes.

The NucliSENS easyMAG is specifically optimized to extract total nucleic acid from biological samples. The system automates an enhanced magnetic silica version of Biomérieux's proprietary BOOM technology, which is based on the ability of silica to bind DNA and RNA in high salt concentrations, according to the company.

"Our last instrument seemed to have a problem extracting RNA viruses and, although it could extract 48 samples at a time, it would take four and a half hours to complete a run," Pauline Furness, senior biomedical scientist at Aberdeen, said in a statement.

Furness added that the lab now has two easyMAG instruments, "each capable of extracting 24 samples in an hour;" and that since the lab started using the instruments it has seen "a considerable increase in sample throughput and a definite improvement in our results."

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.